Normal view MARC view ISBD view

Histone Deacetylase Inhibitors in Combinatorial Anticancer Therapy [electronic resource] / by Shabir Ahmad Ganai.

By: Ganai, Shabir Ahmad [author.]Contributor(s): SpringerLink (Online service)Material type: Text

TextPublisher: Singapore : Springer Singapore : Imprint: Springer, 2020Edition: 1st ed. 2020Description: XVII, 258 p. 27 illus., 13 illus. in color. online resourceContent type: text Media type: computer Carrier type: online resourceISBN: 9789811581793Subject(s): Cancer research | Gene expression | Medical genetics | Nucleic acids | Cancer Research | Gene Expression | Gene Function | Nucleic Acid ChemistryAdditional physical formats: Printed edition:: No title; Printed edition:: No title; Printed edition:: No titleDDC classification: 614.5999 LOC classification: RC261-271Online resources: Click here to access online

Contents:

Chapter 1_Epigenetic modifying enzymes. -Chapter 2_Epigenetic modifying enzymes implicated in cancer. -Chapter 3_Classification of histone deacetylases (HDACs). -Chapter 4_Implications of 18 HDAC isoforms in therapeutically monotonous cancers. -Chapter 5_Possible Mechanisms of HDACs in Cancer development -- Chapter 6_Different strategies employed for circumventing cancer resistance (chemo and radio) and mitigating toxicity. -Chapter 7_Limitations of conventional therapeutic regimens in treating cancer. -Chapter 8_Overview of epidrugs with special emphasis on HDAC inhibitors (HDACi) -- Chapter 9_HDAC inhibitors as promising epidrugs for treating cancer. -Chapter 10_ HDAC inhibitors in anticancer monotherapy. -Chapter 11_Distinct groups of histone deacetylase inhibitors (HDACi) based on the structural distinction, HDACs targeted. -Chapter 12_Limited efficacy of HDAC inhibitor-based monotherapy. -Chapter 13_Resistance mechanisms generated by cancer cells against HDACi based monotherapy. -Chapter 14_ Toxicity issue of HDAC inhibitor based monotherapy. -Chapter 15_Combinatorial therapeutic strategies of HDACi. -Chapter 16_Designing Selective HDACi using computational and medicinal chemistry approach. -Chapter 17. Current therapeutic challenges and future directions. .

In: Springer Nature eBookSummary: This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

Tags from this library: No tags from this library for this title. Log in to add tags.

Holdings ( 1 )
Title notes ( 2 )
Comments ( 0 )

Holdings
Item type	Current library	Call number	Status	Date due	Barcode
Ebooks	Mysore University Main Library		Not for loan

This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.

There are no comments on this title.

to post a comment.